Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

NCT05116579 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Sponsor

Sun Yat-sen University